Liu Lianqi, Fiorentino Lavinia, Natarajan Loki, Parker Barbara A, Mills Paul J, Sadler Georgia Robins, Dimsdale Joel E, Rissling Michelle, He Feng, Ancoli-Israel Sonia
Department of Psychiatry, University of California, San Diego, CA 92161, USA.
Psychooncology. 2009 Feb;18(2):187-94. doi: 10.1002/pon.1412.
The concept of symptom clusters is relatively new in cancer patients' symptom management. This study, which spanned four cycles of chemotherapy, combined three commonly seen pre-treatment symptoms in cancer patients (i.e. sleep disturbances, fatigue and depression) into one symptom cluster, to explore the associations between pre-treatment cluster categories and longitudinal profiles of these same symptoms during chemotherapy.
This was a prospective study. Seventy-six women with newly diagnosed stage I-III breast cancer, scheduled to receive at least four cycles of adjuvant or neoadjuvant anthracycline-based chemotherapy participated. Data were collected at seven time points before and during treatment. Sleep quality was measured with the Pittsburgh Sleep Quality Index. Fatigue was measured with the Multidimensional Fatigue Symptom Inventory--Short Form. Depressive symptoms were measured with the Center of Epidemiological Studies--Depression. Patients were divided into three groups based on the number of symptoms they experienced before the start of chemotherapy (i.e. no symptoms, 1-2 symptoms or all three symptoms) and a symptom cluster index (SCI) was computed.
All women reported worse sleep, more fatigue and more depressive symptoms during treatment compared with baseline (all p's<0.01); however, those women with a higher SCI (i.e. more symptoms pre-treatment) continued to experience worse symptoms during treatment compared with those who began with fewer symptoms (all p's<0.01).
A higher clinically relevant-based pre-treatment symptom cluster was associated with more sleep disturbances, greater fatigue and more depressive symptoms during chemotherapy. Specific interventions for these pre-treatment symptoms may improve the frequency and severity of these same symptoms during chemotherapy, when they are most severe and most disruptive to quality of life.
症状群的概念在癌症患者的症状管理中相对较新。本研究涵盖了四个化疗周期,将癌症患者三种常见的治疗前症状(即睡眠障碍、疲劳和抑郁)合并为一个症状群,以探讨治疗前症状群类别与化疗期间这些相同症状的纵向变化情况之间的关联。
这是一项前瞻性研究。76名新诊断为I - III期乳腺癌的女性参与其中,她们计划接受至少四个周期的基于蒽环类药物的辅助或新辅助化疗。在治疗前和治疗期间的七个时间点收集数据。使用匹兹堡睡眠质量指数测量睡眠质量。使用多维疲劳症状量表简表测量疲劳程度。使用流行病学研究中心抑郁量表测量抑郁症状。根据化疗开始前经历的症状数量(即无症状、1 - 2种症状或三种症状都有)将患者分为三组,并计算症状群指数(SCI)。
与基线相比,所有女性在治疗期间均报告睡眠质量更差、疲劳感更强和抑郁症状更严重(所有p值<0.01);然而,与初始症状较少的女性相比,SCI较高(即治疗前症状较多)的女性在治疗期间症状持续更严重(所有p值<0.01)。
基于临床相关性更高的治疗前症状群与化疗期间更多的睡眠障碍、更强的疲劳感和更严重的抑郁症状相关。针对这些治疗前症状的特定干预措施可能会改善化疗期间这些相同症状的发生频率和严重程度,而此时这些症状最为严重且对生活质量干扰最大。